Advanced Cell Technology
Advanced Cell Technology, Inc. is a leading biotechnology company specializing in regenerative medicine and cellular therapies. The company focuses on developing innovative treatments using stem cell technology, including embryonic stem cells and induced pluripotent stem cells, to address diseases affecting millions worldwide. Their platform includes the production of young, genetically compatible cells for transplantation, with ongoing clinical trials for retinal degenerative diseases and other conditions. ACT is committed to advancing regenerative medicine through groundbreaking research and clinical development.
Industries
Nr. of Employees
small (1-50)
Advanced Cell Technology
Products
hESC-derived retinal pigment epithelial (RPE) cell therapy (clinical-stage)
A cell therapy product consisting of retinal pigment epithelial cells derived from pluripotent stem cells intended for subretinal transplantation to treat retinal degenerative diseases such as Stargardt’s disease and dry age-related macular degeneration; advanced into Phase I/II clinical studies.
Hemangioblast (HG) platform for blood and cardiovascular diseases
A pluripotent cell-derived platform focused on producing hemangioblast derivatives for potential treatment of hematologic and cardiovascular conditions; developed in collaboration with external partners.
Autologous myoblast cell therapy for cardiac disease (Phase II-cleared program)
An autologous myoblast-based cellular therapy program targeting chronic heart failure and other cardiac conditions, with prior regulatory clearance to Phase II.
hESC-derived retinal pigment epithelial (RPE) cell therapy (clinical-stage)
A cell therapy product consisting of retinal pigment epithelial cells derived from pluripotent stem cells intended for subretinal transplantation to treat retinal degenerative diseases such as Stargardt’s disease and dry age-related macular degeneration; advanced into Phase I/II clinical studies.
Hemangioblast (HG) platform for blood and cardiovascular diseases
A pluripotent cell-derived platform focused on producing hemangioblast derivatives for potential treatment of hematologic and cardiovascular conditions; developed in collaboration with external partners.
Autologous myoblast cell therapy for cardiac disease (Phase II-cleared program)
An autologous myoblast-based cellular therapy program targeting chronic heart failure and other cardiac conditions, with prior regulatory clearance to Phase II.
Services
GMP-compliant production and release of cellular therapy products for clinical trials, including facilities and processes for producing hESC-derived cell populations.
Derivation, characterization, and registration-support for human embryonic stem cell lines using an embryo-safe single-blastomere technique and standard characterization assays.
GMP-compliant production and release of cellular therapy products for clinical trials, including facilities and processes for producing hESC-derived cell populations.
Derivation, characterization, and registration-support for human embryonic stem cell lines using an embryo-safe single-blastomere technique and standard characterization assays.
Expertise Areas
- Therapeutic cloning and somatic cell nuclear transfer
- Human embryonic stem cell derivation and characterization
- Differentiation to retinal pigment epithelium and retinal cell therapies
- Preclinical animal models for regenerative medicine
Key Technologies
- Somatic cell nuclear transfer
- Single-blastomere hESC derivation
- Directed differentiation to retinal pigment epithelium (RPE)
- Protein-based induction of pluripotency
News & Updates
ACT has developed a human embryonic stem cell-based therapy using retinal pigment epithelial (RPE) cells to treat blindness-causing retinal degenerative diseases, with ongoing clinical trials.
ACT received FDA clearance to initiate a Phase I/II clinical trial using retinal cells derived from human embryonic stem cells to treat Stargardt’s Macular Dystrophy, a form of juvenile macular degeneration.
ACT reported evidence that nuclear transplantation can generate immune-compatible tissues, tested in cows, which may eliminate tissue rejection in transplantation.
ACT reached an agreement with the Spanish government to clone the extinct bucardo mountain goat using interspecies nuclear transfer technology.
ACT’s RPE cells were granted orphan drug status by the FDA for the treatment of Stargardt’s Macular Dystrophy, facilitating accelerated development and market exclusivity.
ACT has developed a human embryonic stem cell-based therapy using retinal pigment epithelial (RPE) cells to treat blindness-causing retinal degenerative diseases, with ongoing clinical trials.
ACT received FDA clearance to initiate a Phase I/II clinical trial using retinal cells derived from human embryonic stem cells to treat Stargardt’s Macular Dystrophy, a form of juvenile macular degeneration.
ACT reported evidence that nuclear transplantation can generate immune-compatible tissues, tested in cows, which may eliminate tissue rejection in transplantation.
ACT reached an agreement with the Spanish government to clone the extinct bucardo mountain goat using interspecies nuclear transfer technology.
ACT’s RPE cells were granted orphan drug status by the FDA for the treatment of Stargardt’s Macular Dystrophy, facilitating accelerated development and market exclusivity.